TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16905783

Group type: EXPERIMENTAL
Intervention: 3-drug regimen (Zidovudine/lamivudine plus efavirenz)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: 4-drug regimen (Zidovudine/lamivudine/abacavir plus efavirenz)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: 3-drug regimen
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: 4-drug regimen
Number of subjects: 765
Study: 15592270

Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel (37.5 mg metronidazole per dose), once nightly for 5 nights
Number of subjects: 151

Group type: COMPARATOR
Intervention: Metronidazole 500 mg plus nystatin 100,000 U ovules, once nightly for 5 nights
Number of subjects: 151
Study: 11485952

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate at a dose of 200 microg/day
Number of subjects: 2324

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate at doses of 100-250 microg/day
Number of subjects: 2324

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate at a dose of around 500 microg/day
Number of subjects: 2324
Study: 9441148

Group type: EXPERIMENTAL
Intervention: Induced labor (artificial rupture of membranes and oxytocin infusion)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Spontaneous labor
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Induced labor
Number of subjects: 400
Study: 7964952

Group type: EXPERIMENTAL
Intervention: Five-drug regimen (etoposide, thioguanine, dexamethasone, daunorubicin, and cytarabine)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Standard regimen (cytarabine and daunorubicin, 7 + 3)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Intensive chemotherapy consolidation
Number of subjects: 591

Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 591
Study: 2444802

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-selective antagonist)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Labetalol (combined alpha/beta-receptor blockade)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of Labetalol and Metoprolol
Number of subjects: 14
Study: 28945936

Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Glucose Monitoring System™
Number of subjects: 465
Study: 27732947

Group type: EXPERIMENTAL
Intervention: Clinical trial patients
Number of subjects: 867

Group type: COMPARATOR
Intervention: Patients treated off-trial
Number of subjects: 867
Study: 25539791

Group type: EXPERIMENTAL
Intervention: LY40 mg BID
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: LY80 mg BID
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Risperidone (RIS) 2 mg BID
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1013
Study: 22277604

Group type: EXPERIMENTAL
Intervention: Rapid Prototyping (RP) method
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 10
Study: 20409331

Group type: EXPERIMENTAL
Intervention: 80 mg Methylprednisolone + 10 mg Lidocaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 40 mg Methylprednisolone + 10 mg Lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline + 10 mg Lidocaine (placebo)
Number of subjects: 120
Study: 18455517

Group type: EXPERIMENTAL
Intervention: 1000 mg/day vitamin C
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin E
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 16155267

Group type: EXPERIMENTAL
Intervention: High-protein diet (21% of energy as protein)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-protein diet (9% of energy as protein)
Number of subjects: 20
Study: 12717099

Group type: EXPERIMENTAL
Intervention: Allopurinol (400 mg) administered orally just after admission (60 min before reperfusion)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no allopurinol treatment)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Allopurinol treatment group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 10961032

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 568
Study: 9459673

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (15 sessions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 27
Study: 8333258

Group type: EXPERIMENTAL
Intervention: Fusidic acid viscous eye drops 1% given twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloramphenicol eye drops 0.5% given 6 times daily
Number of subjects: 0
Study: 3511401

Group type: EXPERIMENTAL
Intervention: High-dosage trihexyphenidyl (30 mg)
Number of subjects: 31
Study: 31600365

Group type: EXPERIMENTAL
Intervention: FTD/TPI
Number of subjects: 507
Study: 30194737

Group type: EXPERIMENTAL
Intervention: Educational program only
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Educational program plus 1% chlorhexidine varnish monthly application
Number of subjects: 81

Group type: COMPARATOR
Intervention: Current oral hygiene practice (control)
Number of subjects: 81
Study: 26769910

Group type: EXPERIMENTAL
Intervention: Mobile Diabetes Detective (MoDD)
Number of subjects: 15
Study: 24650843

Group type: EXPERIMENTAL
Intervention: Mobile technology intervention (n=26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control condition (n=25)
Number of subjects: 51
Study: 22739325

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (n = 10)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low-intensity cycling (LIC; n = 10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Seated rest (CON; n = 6)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pain scale (PS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isometric strength (ISO)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dynamic strength (PT)
Number of subjects: 26
Study: 18786585

Group type: EXPERIMENTAL
Intervention: RIX4414 + OPV
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo + OPV
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 450
Study: 18947472

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus prednisone
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (pulse intravenous infusion of cyclophosphamide (CTX) plus prednisone)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (pulse intravenous infusion of cyclophosphamide (CTX))
Number of subjects: 142
Study: 15900990

Group type: EXPERIMENTAL
Intervention: MyStudentBody.com: Alcohol (MSB:Alcohol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control alcohol education Web site
Number of subjects: 0
Study: 12598347

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone (160 mg day 1, then 20 mg/day for 5 years)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Surgery plus tamoxifen (20 mg/day for 5 years)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 474

Group type: COMPARATOR
Intervention: Surgery plus tamoxifen
Number of subjects: 474
Study: 11091983

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8633818

Group type: EXPERIMENTAL
Intervention: Exercise training (3 sessions per week for 24 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study: 1515385

Group type: EXPERIMENTAL
Intervention: 100 micrograms epinephrine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 200 micrograms epinephrine
Number of subjects: 69

Group type: COMPARATOR
Intervention: No epinephrine (Control)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients weighing more than 90.8 kg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients weighing less than 90.8 kg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 100 micrograms epinephrine (subset)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 200 micrograms epinephrine (subset)
Number of subjects: 69
Study: 3975326

Group type: EXPERIMENTAL
Intervention: Women informed of the interest in menstrual cycle symptomatology
Number of subjects: 27

Group type: COMPARATOR
Intervention: Women and men not informed of the interest in menstrual cycle symptoms
Number of subjects: 27
Study: 30688410

Group type: EXPERIMENTAL
Intervention: Preprandial metformin administration (500-1,000 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Postprandial metformin administration (500-1,000 mg)
Number of subjects: 11
Study: 29430940

Group type: EXPERIMENTAL
Intervention: Elastic tubes with handles group (ETG)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Traditional elastic bands group (EG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: ETG vs CG
Number of subjects: 63
Study: 26682789

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) ON
Number of subjects: 66

Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS) OFF
Number of subjects: 66
Study: 25064164

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 100 mg/kg/dose administered every 6 hours until delivery
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 100 mg/kg/dose
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 12.5-25 mg/kg/dose administered every 12 hours for 5 doses
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline administered within 4 hours of CA diagnosis
Number of subjects: 11
Study: 22633469

Group type: EXPERIMENTAL
Intervention: 3D brachytherapy (BT)
Number of subjects: 705

Group type: COMPARATOR
Intervention: 2D brachytherapy (BT)
Number of subjects: 705
Study: 20878879

Group type: EXPERIMENTAL
Intervention: Immediate release carbamazepine products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulated saliva samples (chewing on parafilm wax and spitting method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro dissolution testing with 1% sodium lauryl sulphate
Number of subjects: 0
Study: 17593161

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 12 weeks
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 157
Study: 16203960

Group type: EXPERIMENTAL
Intervention: Usual care plus abstinence-based incentives for 12 weeks
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study: 11943936

Group type: EXPERIMENTAL
Intervention: Desmopressin (300 microg nasal inhalation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmopressin (combined with tranexamic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9951357

Group type: EXPERIMENTAL
Intervention: Intensive acupuncture treatment (25 sessions over 2 months, 30 minutes each)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 54
Study: 7844609

Group type: EXPERIMENTAL
Intervention: IL-1 beta (0.005 to 0.2 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-1 beta (0.005 to 0.05 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-1 beta (0.1 to 0.2 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Number of subjects: 20
Study: 2309545

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intramuscular pethidine (75 mg)
Number of subjects: 96
Study: 393363

Group type: EXPERIMENTAL
Intervention: Minocycline 300 mg
Number of subjects: 241

Group type: COMPARATOR
Intervention: Ampicillin 2 g and probenecid 1 g
Number of subjects: 241
Study: 31770617

Group type: EXPERIMENTAL
Intervention: Preventive treatment with rifapentine and isoniazid
Number of subjects: 513

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 513
Study: 30793411

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 29324935

Group type: EXPERIMENTAL
Intervention: Artificial neural network classifier using 123I-FP-CIT brain SPET data (CIT)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CIT decision rule for right putamen uptake
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Further analysis for patients with right putamen values ≥2.32
Number of subjects: 187
Study: 25764229

Group type: EXPERIMENTAL
Intervention: Structured personalized report containing information on all nine diabetes care processes
Number of subjects: 14559

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 14559
Study: 23499158

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 200 mg + peginterferon + ribavirin
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg + peginterferon + ribavirin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo + peginterferon + ribavirin
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg + peginterferon + ribavirin (cohort B)
Number of subjects: 147
Study: 21196616

Group type: EXPERIMENTAL
Intervention: Ureteral spatulation ≥ 10 mm (group 2)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Ureteral spatulation ≤ 10 mm (group 1)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy (PCN) and balloon dilatation for ureteral stenosis
Number of subjects: 170
Study: 19585548

Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) (28-30 mg/kg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA)
Number of subjects: 150
Study: 17919823

Group type: EXPERIMENTAL
Intervention: Dacarbazine monotherapy
Number of subjects: 7135

Group type: EXPERIMENTAL
Intervention: Dacarbazine with interferons
Number of subjects: 7135

Group type: COMPARATOR
Intervention: Other treatments (alone or in combination)
Number of subjects: 7135
Study: 15372386

Group type: EXPERIMENTAL
Intervention: 2 mg morphine in 20 mL of 0.9% NaCl solution (5 mL of solution per point) 10 minutes before the operation (Group M)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2 mg morphine in 20 mL of 0.25% bupivacaine (Group M+B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 20 mL 0.9% NaCl (Group S)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 20 mL of 0.9% NaCl with 2 mg of subcutaneous morphine 10 minutes before surgery (Group S+M)
Number of subjects: 150
Study: 11519927

Group type: EXPERIMENTAL
Intervention: Chronic causal uncertainty beliefs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated accuracy goal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primed causal uncertainty beliefs
Number of subjects: 0
Study: 9605677

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 12
Study: 8169104

Group type: EXPERIMENTAL
Intervention: Computer program plus dissection
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Computer program alone
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Dissection alone
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 175
Study: 3253222

Group type: EXPERIMENTAL
Intervention: Carbolevure
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 5046478

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 0
Study: 30160436

Group type: EXPERIMENTAL
Intervention: Non-elastic tape (experimental group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tape (control group)
Number of subjects: 28
Study: 28993451

Group type: COMPARATOR
Intervention: Typical American diet (control)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 412

Group type: COMPARATOR
Intervention: DASH diet vs control
Number of subjects: 412
Study: 26875275

Group type: EXPERIMENTAL
Intervention: Sandiwich combined with artificial bone of tricalcium phosphate (trial group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sandiwich (control group)
Number of subjects: 85
Study: 22795904

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 21628102

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 18980474

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monosialotetrahexosylganglioside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early surgical decompression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical field stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking Nogo and Rho
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transplantation of various cellular substrates
Number of subjects: 0
Study: 17138713

Group type: EXPERIMENTAL
Intervention: Needle bevel oriented away from the mandibular ramus
Number of subjects: 51

Group type: COMPARATOR
Intervention: Needle bevel oriented toward the mandibular ramus
Number of subjects: 51
Study: 12713066

Group type: EXPERIMENTAL
Intervention: Zidovudine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine + Didanosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine + Zalcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual nucleoside combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 0
Study: 11103655

Group type: EXPERIMENTAL
Intervention: Pregnant adolescents
Number of subjects: 156

Group type: COMPARATOR
Intervention: Pregnant adults
Number of subjects: 156
Study: 9373762

Group type: EXPERIMENTAL
Intervention: linotroban
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 1392111

Group type: EXPERIMENTAL
Intervention: Topical lithium succinate ointment (LSO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 4002806

Group type: EXPERIMENTAL
Intervention: 10 mg M/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: 20 mg M/day
Number of subjects: 21
Study: 31607561

Group type: EXPERIMENTAL
Intervention: High-cost patients with NIIEDs
Number of subjects: 14879
Study: 29067867

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 10
Study: 27153158

Group type: EXPERIMENTAL
Intervention: Intradermal injection of 9 µg of hemagglutinin (HA) per strain
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intramuscular injection of 15 µg of HA per strain
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intradermal injection
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intramuscular injection
Number of subjects: 149
Study: 24461315

Group type: EXPERIMENTAL
Intervention: Cinnamon (1500 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (2 capsules daily)
Number of subjects: 50
Study: 22260857

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF) (20% fat)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-fat high-omega-3 diet (LFn3) (23% fat with 3% as α-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid [DHA])
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-fat diet (HF) (40% fat)
Number of subjects: 17
Study: 21049063

Group type: EXPERIMENTAL
Intervention: 20 mg/kg/day of paromomycin for 21 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day of paromomycin for 28 days
Number of subjects: 42
Study: 17984140

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg on the first day followed by 50 mg/kg/day for three days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 27
Study: 15793648

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 88
Study: 11958351

Group type: EXPERIMENTAL
Intervention: Compound cue AT followed by an outcome (AT+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: A alone paired with the outcome (A+)
Number of subjects: 0
Study: 10606360

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg BID)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8961043

Group type: COMPARATOR
Intervention: Fluoxetine (not specified dosage or duration)
Number of subjects: 137
Study: 1761079

Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl 5, 10, 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl 30 mg
Number of subjects: 30
Study: 7017886

Group type: COMPARATOR
Intervention: Brain cortex phospholipids (BC-PL)
Number of subjects: 0
Study: 31980871

Group type: COMPARATOR
Intervention: Diltiazem gel 2%
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Levorag® Emulgel
Number of subjects: 55
Study: 30922355

Group type: EXPERIMENTAL
Intervention: Binafuxi granules (high-dose group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Binafuxi granules (low-dose group)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 240
Study: 27783968

Group type: EXPERIMENTAL
Intervention: Forced diuresis with matched controlled hydration (FMH)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Matched historical control cohort
Number of subjects: 150
Study: 27601545

Group type: EXPERIMENTAL
Intervention: Radiation therapy and 6 months of ADT
Number of subjects: 206

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 206
Study: 24868564

Group type: EXPERIMENTAL
Intervention: Wavefront‐guided (WFG) PRK
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wavefront‐optimized (WFO) PRK
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71